Meeting
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
Authors
Pankit Vachhani
O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL
Pankit Vachhani , Vikas Gupta , Francesca Palandri , Purvi Suthar , Sarah Buckley , Karisse Roman-Torres , Prithviraj Bose
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT02055781
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6578)
DOI
10.1200/JCO.2024.42.16_suppl.6578
Abstract #
6578
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
First Author: Haris Ali
Poster
2024 ASCO Annual Meeting
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.
First Author: Stephen Oh
Poster
2023 ASCO Annual Meeting
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
First Author: Aaron Thomas Gerds
Poster
2023 ASCO Annual Meeting
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.
First Author: Yi Zhang